RxDoctor Payments Data

Grace Imson, MD

Internal Medicine · Miami, FLNPI 1154552180

Payments from drug & device makers

$1,882in general payments, 2019–2025

Across 89 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$753
  • Novo Nordisk$223
  • Exact Sciences$209
  • Novartis$123
  • Viiv Healthcare Company$118
  • Lilly USA, LLC$90
  • plus $367 from 12 others

What the payments were for

  • Food & beverage$1,79795%
  • Education$855%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,882 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$81,435
Medicare patients
240
Services billed
1,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$114,321
EliquisApixaban49$53,312
JanuviaSitagliptin Phosphate40$45,290
JardianceEmpagliflozin31$34,646
XareltoRivaroxaban26$29,558
EpidiolexCannabidiol (Cbd)14$28,742
TrulicityDulaglutide14$25,832
JanumetSitagliptin Phos/Metformin Hcl13$21,783
Repatha SureclickEvolocumab19$21,147
RybelsusSemaglutide11$18,329
FarxigaDapagliflozin Propanediol16$14,191
MounjaroTirzepatide13$13,480
LinzessLinaclotide12$7,494
Atorvastatin Calcium630$5,727
SymbicortBudesonide/Formoterol Fumarate15$4,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$223$132,650123 claims
Lilly USA, LLCTrulicity, Mounjaro$90$39,31227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →